A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma

Share

Full Title

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

Purpose

Researchers want to see if the drug nanatinostat, alone or with valganciclovir, is useful for treating lymphoma. The people in this study have Hodgkin or non-Hodgkin lymphoma that keeps growing even after treatment. In addition, their lymphomas have the Epstein-Barr virus (EBV).

Valganciclovir is an antiviral drug (a drug that fights against a virus). Antiviral drugs have been shown to destroy some EBV-positive cancer cells. However, these drugs don’t work unless the virus is active inside the tumor cell. Nanatinostat may activate the EBV-positive cancer cells and make them more sensitive to valganciclovir.

If you join this study, you will get nanatinostat or with valganciclovir. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have Hodgkin lymphoma or non-Hodgkin lymphoma that is positive for EBV and keeps growing even though you had treatment.
  • Not be able to have a stem cell transplant or CAR T cell therapy.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Zachary Epstein-Peterson’s office at 646-608-4176.

Protocol

23-115

Phase

Phase II (phase 2)

Disease Status

Relapsed or Refractory

Co-Investigators

ClinicalTrials.gov ID

NCT05011058